Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HEC73077 tablets
HEC73077 · 1 trial · 1 indication
Incidence of adverse events
Maximum plasma concentration of study drugs
area under the concentration versus time curve (AUC) from time zero to infinity
| Arm | Type | Description |
|---|---|---|
| HEC73077 tablets | EXPERIMENTAL | Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts. |
| HEC73077 placebo tablets | PLACEBO_COMPARATOR | Single-Dose Study: There will be a total of 7 dose cohorts. Multiple-dose Study: There will be a total of 4 dose cohorts. |
| Name | Type | Description |
|---|---|---|
| HEC73077 tablets | DRUG | Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study. |
| HEC73077 placebo tablets | DRUG | Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight. Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study. |
Inclusion Criteria: 1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. 2. Be able to complete the study according to the trail protocol. 3. Subjects (including partners) have no pregnancy plan within 6 month...
Top 3 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Rilparencel |
HEC73077 is an investigational small molecule developed by Sunshine Biopharma Inc. (ticker SBFM) for diabetic nephropathy, a kidney complication of diabetes. It is in Phase 1 clinical development and has been studied in a completed Phase 1 trial in healthy subjects in China.
HEC73077 is being developed for diabetic nephropathy, a kidney condition that occurs in people with diabetes. It is an investigational therapy and has not been approved for any indication. Its clinical work to date has been in healthy volunteers rather than in patients with diabetic nephropathy.
HEC73077 is developed by Sunshine Biopharma Inc., which trades under the ticker SBFM. The company is the sponsor behind the drug's clinical development program in diabetic nephropathy.
HEC73077 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program has not advanced beyond Phase 1, and the drug remains investigational for diabetic nephropathy.
HEC73077 has been evaluated in one completed Phase 1 trial, NCT05492630, titled a single and multiple dose safety, tolerability, PK and food effect study in healthy subjects. The trial enrolled 138 participants in China, was randomized, double blind, and placebo controlled, and included adults 18 years and older.
Yes, HEC73077 tablets refers to the same investigational drug as HEC73077. The tablet form is the oral formulation studied in the Phase 1 trial of the small molecule for diabetic nephropathy.